“Atropos Health announced a partnership with pharmaceutical giant Novartis, {beginning with an AI model} to help identify individuals with the rare disease paroxysmal nocturnal hemoglobinuria (PNH) who have not yet been diagnosed. PNH is a rare blood disorder of the hematopoietic stem cells, where the body’s immune system attacks red blood cells. Patients present clinically with a variety of nonspecific symptoms, and the disease can cause bone marrow failure, thrombosis and intravascular hemolysis.”
Atropos Health, Novartis partner for earlier detection of rare blood disorder
